NO20090165L - Kombinasjonsfremstillinger innbefattende bifeprunox og L-DOPA - Google Patents

Kombinasjonsfremstillinger innbefattende bifeprunox og L-DOPA

Info

Publication number
NO20090165L
NO20090165L NO20090165A NO20090165A NO20090165L NO 20090165 L NO20090165 L NO 20090165L NO 20090165 A NO20090165 A NO 20090165A NO 20090165 A NO20090165 A NO 20090165A NO 20090165 L NO20090165 L NO 20090165L
Authority
NO
Norway
Prior art keywords
bifeprunox
dopa
preparations including
combination preparations
simultaneous
Prior art date
Application number
NO20090165A
Other languages
English (en)
Inventor
Gustaaf Johan Marie Van Scharrenburg
Martinus Th M Tulp
Andrew C Mccreary
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20090165L publication Critical patent/NO20090165L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår anvendelsen av et kombinasjonspreparat av bifeprunox eller dets N-oksid, eller farmakologisk akseptable salter av disse forbindelsene, for samtidig, separat eller sekvensiell anvendelse i behandlingen av lidelser som krever gjenvinning av dopaminergisk funksjon, spesielt Parkinsons sykdom og "Restless Leg"-syndrom.
NO20090165A 2006-06-16 2009-01-12 Kombinasjonsfremstillinger innbefattende bifeprunox og L-DOPA NO20090165L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81405206P 2006-06-16 2006-06-16
EP06115587 2006-06-16
PCT/EP2007/055956 WO2007144422A2 (en) 2006-06-16 2007-06-15 Combination preparations comprising bifeprunox and l-dopa

Publications (1)

Publication Number Publication Date
NO20090165L true NO20090165L (no) 2009-01-12

Family

ID=38691894

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090165A NO20090165L (no) 2006-06-16 2009-01-12 Kombinasjonsfremstillinger innbefattende bifeprunox og L-DOPA

Country Status (9)

Country Link
EP (1) EP2037964A2 (no)
JP (1) JP2009539942A (no)
KR (1) KR20090033871A (no)
AU (1) AU2007259256A1 (no)
CA (1) CA2654557A1 (no)
EA (1) EA014576B1 (no)
IL (1) IL195493A0 (no)
NO (1) NO20090165L (no)
WO (1) WO2007144422A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009265760B2 (en) * 2008-06-30 2013-07-18 Novartis Ag Combinations comprising mGluR modulators for the treatment of parkinson's disease
ITMI20100260A1 (it) * 2010-02-19 2011-08-20 Giulio Scigliano Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
PL2627328T3 (pl) * 2010-10-15 2017-03-31 Contera Pharma Aps Połączenia agonistów receptorów serotoninowych do stosowania w leczeniu zaburzeń ruchowych
NZ700474A (en) 2012-04-18 2016-10-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
TWI755257B (zh) 2014-10-21 2022-02-11 美商艾伯維有限公司 卡比多巴及左旋多巴之前藥及使用方法
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045362A1 (es) * 2003-08-18 2005-10-26 Solvay Pharm Bv Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona

Also Published As

Publication number Publication date
AU2007259256A1 (en) 2007-12-21
EP2037964A2 (en) 2009-03-25
WO2007144422A3 (en) 2008-03-13
CA2654557A1 (en) 2007-12-21
KR20090033871A (ko) 2009-04-06
JP2009539942A (ja) 2009-11-19
EA014576B1 (ru) 2010-12-30
WO2007144422A2 (en) 2007-12-21
IL195493A0 (en) 2009-09-01
EA200970022A1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
NO20090165L (no) Kombinasjonsfremstillinger innbefattende bifeprunox og L-DOPA
JO2756B1 (en) The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use)
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
NO20065878L (no) Terapeutiske forbindelser
SI2142193T1 (sl) 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazin kot spojina s kombiniranim vnosom serotonina, 5-ht3 in 5-hta1 aktivnostjo za zdravljenje boleäśine ali ostalih simptomov pri depresiji v zvezi s spanjem in kognicijo
DK2004225T3 (da) Programmer for vaccination med meningocockonjugater
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
BR0309185A (pt) Medicamento contendo beta-miméticos e um novo anticolinérgico
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
DK2175877T3 (da) Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme
WO2007144699A3 (en) Process for the preparation of alfuzosin
NO20090164L (no) Kombinasjonsfremstillinger innbefattende SLV308 og en L-DOPA
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
UY31131A1 (es) "oxazolidinonas sustituidas y su uso
UA94461C2 (ru) Водный экстракт листьев табака и его применение для лечения состояния зависимости
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
UA94466C2 (ru) Комбинированные препараты с содержанием slv308 и l-dopa
UA94465C2 (ru) Комбинированные препараты с содержанием бифепрунокса и l-dopa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application